一种可注射的多功能水凝,用于通过调节氧化应激和炎症微环境来进行心脏时空修复
Jiajun Lu1, Jing Chen2, Linken Lu1
1School of Basic Medical Sciences, North China University of Science and Technology, Tangshan 063210, China. sunhong@ncst.edu.cn.
Journal of materials chemistry. B
|December 2, 2025
概括
一种新的可注射水凝 (CPH) 通过减少氧化应激和炎症,有效治疗心肌梗塞 (MI). 这种生物材料促进心脏修复,并改善心脏功能后心脏病发作,为再生医学提供了潜力.
科学领域:
- 生物材料科学 生物材料科学
- 心血管研究研究心血管研究
- 再生医学是一种再生医学.
背景情况:
- 心肌梗塞 (MI) 是由于氧化应激和炎症导致的显著心血管死亡的原因.
- 目前的治疗方法不足以解决MI后的病态微环境.
- 需要先进的生物材料来促进心脏修复和再生.
研究的目的:
- 开发一种可注射的水凝系统 (CPH) 用于治疗心肌梗塞.
- 创建一个仿制本地心肌细胞外基质的生物材料,具有多功能性质.
- 评估CPH水凝在体外和体内治疗的疗效.
主要方法:
- 开发了一种可注射的水凝 (CPH),使用了碳甲基 (CMCS),酸 (DS) 和氧化 (ODex).
- 评估了水凝的机械性质,抗氧化剂,抗炎性,益血管性和电气性质.
- 进行了细胞研究和老鼠MI模型来评估治疗效果.
主要成果:
- CPH水凝模仿了原生心肌细胞外基质的特性.
- 证明了抗氧化,抗炎和益血管效应,清除ROS和保护心肌细胞.
- 在老鼠MI模型中显示了增强的血管再生和心肌重塑,改善心脏功能.
结论:
- CPH水凝是一种创新的无细胞治疗方法,用于MI.
- 这种生物材料推进了心脏组织工程,具有显著的临床翻译潜力.
- CPH水凝提供全面的结构恢复和功能改善后MI.
更多相关视频
06:15A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.
Published on: June 14, 2015
9.2K
09:19Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model
Published on: September 20, 2020
4.8K
相关概念视频
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
